The key technology of Patient Derived Tumor Spheroids (PDTS) is to create an in-vitro patient tumor microenvironmenttumor-like properties, furthermore, predict various cancer antidrug effectiveness to each patient via the high-throughputhigh-quality cell viability detectionbiomarker analysis. Therefore, this project established several technologies including extracellular matrix fabrication, bioink design, cell population identification,tumor physiological environment for the upon goal.

This technology is used to reveal the immune profiling of the tumor microenvironment based on multi-color immunohistochemistry staining. Each immune cell type will be probed with different fluorophores,the density, as well as the location of each immune cell type on the tissue slides, will be disclosed using inForm software.

PCA-BM includes two models: “Automatic BMs Segmentation AI Model”" Distant Brain Failure Prediction Model". The former one uses C2FNAS (coarse to fine network architecture search) to detect the location, size,number of brain metastases. The latter uses radiomics to extract numerous radiographic featuresemploys machine learning methods such as XGBoost to establish a prognostic model of brain metastases. PCA-BM provides more precision treatment decisions for patientsimproves personalizedaccurate overall stereotactic radiosurgery planning.

This technology is a development drug lead aiming to meet the medical needs of patients with small cell lung cancer. Through disturbing MYC-Aurora A interaction and inducing degradation of MYC oncoprotein, this bioavailable kinase inhibitor could serve as a potential treatment entity for SCLC.

R3CE (Rapid, Reproducible, Rare Cell 3D Expansion) is a clinically validated platform capable of generating single cell-derived organoids within one to four weeks. It outperforms currently 3D culture technologies in terms of yields, time to form organoids,easiness of operation. It also demonstrates similar yieldscost structure to 2D culture protocols. R3CE is ready for drug testing for all clinical samplesprovides sufficient quantity of genomic samples derived from cancer patients. It would help conduct clinical cancer treatment in the translational study.

DBPR807 can significantly suppress tumor growth, prevent distant metastasis, reduce angiogenesis, normalize tumor microenvironment and promote cytotoxic T-cell infiltration. In various HCC models, DBPR807 itself can prolong overall survival as effectively as marketed anti-angiogenic agent sorafenib and immune checkpoint inhibitor anti-PD-1 Ab. What’s more, its combination therapy with either sorafenib or anti-PD-1 Ab can extend life expectancy even more significantly than aforementioned monotherapy.

In the current of study, cell subsets, cell proportionsthe immune function of tumors-infiltrating leukocytes were used to indicate the features of tumor immune microenvironment in non-small cell lung cancers (NSCLCs) with different type of EGFR genetic alteration.

We have identified a series of BPR1R compounds as highly selective CSF1R inhibitors with excellent oral bioavailability. In vivo, oral administration of BPR1R compounds delayed murine colon tumor growthreversed the immunosuppressive TME with increased M1/M2 ratio. The US & PCT patent application including more than 160 novel compounds was filed in April 20, 2020. Several potential compounds are undergoing candidate assessment for further preclinical studies.

"The primary goal of this project is to establish a complete hospital-based liver cancer database, profiles for data feature extraction,develop different cancer, prediction models. A Medical AI program to predict the poster treatment (including operationradiofrequency ablation) recurrence of liver cancer will be established. The program system will assist doctors in the medical decision, identify high-risk patients,adjust clinical follow-up programs."

The RL model develops a control policy directly from experience to predict statesrewards during a learning procedure. Hence, we designed a medical image environment including US images, different actions,rewards, agent learns in this environment to extract the ALN regionevaluates the status. The performance of our proposed method achieves an accuracy of 83.6, a sensitivity of 88.6,a specificity of 89.0.

These stimuli-switchable nanoparticles coated with the cleavable outer polymer coatingmultifunctional peptides may afford a new platform for anticancer drugmiR. These nanoparticles possess characteristics of environmental response, active targeting,gene/chemo combinatorial therapeutics, thus providing spatiotemporal control of posttranｓｃｒｉｐｔional gene regulation, smart nuclear/mitochondrial localization,simultaneous inhibition of multiple progression pathways of tumor cells for enhancing antitumor efficacysafety of cancer therapy.

A microfluidic diffraction device is developed for determination of CTC/bacteria from human whole blood with a home-constructed laser beam system. We design the optical structuretransfer the structure to transparent plastic substrate. The plastic diffraction die is modified with antibodies of the target to combine a fluidic system as a microfluidic diffraction chip. When human whole blood with CTCs/bacteria flows through the chip, the number of cells/bacteria can be obtained directly with label-free. The devices has been applied in clinical diagnosis of oesophagealendometrial cancer.

Ninety percent of human diseases are related to abnormal inflammation. WJM team has successfully developed a new monoclonal antibody that can inhibit a key inflammation protein. Animal experiments have accumulated more than ten disease modes, including a variety of solid tumors, fibrosis, degenerativecardiovascular diseases. This antibody is qualified as an orphan drug for the treatment of IPF. New coronary pneumonia has greatly increased the demand for pulmonary fibrosis treatment,has also become an important target for mergersacquisitions of global pharmaceutical companies.

Nanopharmaterial is a term by combining pharmaceuticalmaterial via nanotechnology. Here we demonstrate this concept by developing a novel nanopharmaterial, so called 177Lu-Gold nanostar (AuNS). 177Lu is a therapeutic radionuclide emitting moderate-energy beta particles as well as gamma rays for SPECT/CT-based imaging diagnosis. Nanostar can target tumors by enhanced permeability retention (EPR) effectsowns the photothermal therapeutic potent. The core technology is to integrate radionuclidenanomaterial to perform a new radio-nanopharmaterial for tumor target theranostic purpose.

This breaking-through technology aims at designingconstructing a compliant prone-type ring-scanning inspection platform incorporated with a simultaneous multi-frequency driving NIR light source to complete a diffuse optical imaging system. The realized system has two features superior to other counterpart imaging equipments: (i) compliant flexible optical channels to collect optical information,(ii) simultaneous multiple frequency driving light source. It brings the benefits to improve the accuracy of reconstructed imagesshorten examination time for test subjects.

Effectively inducing cytotoxic T cell expansion has been a critical challenge in vaccine development. To address this challenge, an entirely biodegradable polymeric nanoshell was invented to couple antigensadjuvants for safepotent immune potentiation. The invention has been adopted for precision anticancer vaccine, broadly reactive influenza vaccine,an effective vaccine MERS-CoV.

PANCREASaver contains a “PC automatic segmentation model” (image segmentation)a “PC analysis AI model” (image classification) that can read the DICOM format of postcontrast CT images directly for the automatic analysis process. After conducting prep-processing with image processing algorithms, C2FNAS is employed to illustrate the tumor position prior to the diagnosis conducted by CNN. The results can be provided to the physician for diagnostic reference so as to reduce early omissionsincrease the detection rate of pancreatic cancer.